Pluristem Life Systems, Inc. has announced that favorable results have been obtained in pre-clinical testing using the Company’s proprietary PLX cells to treat limb ischemia, a potential market of over $1 Billion.
Mr. Zami Aberman, Pluristem Chairman and CEO commented, “These results are encouraging and suggest that our PLX cells may be the first allogeneic, off-the-shelf product to treat this serious disease.” PLX cells are placenta derived mesenchymal stem cells expanded in the Company’s proprietary PluriX™ 3-D bioreactor system.
Scientists administered Pluristem’s proprietary PLX cells in vivo to one set of ischemic mice. Post-treatment evaluation using Doppler technology indicated revascularization of the limb treated with PLX cells but not in those that were not treated with PLX. The hind legs of mice were rendered ischemic using standard industry methodologies.
Industry experts have estimated that therapeutics used in the treatment of limb ischemia market is over $1 Billion. However, current therapeutic methodologies have proven ineffective for many severe limb ischemic situations and led the medical community to call for the development of cellular therapies, such as Pluristem’s PLX cells and other methods as alternative treatments.